Possibility of maintaining remission with topical therapy alone after withdrawal of dupilumab in Japanese patients with atopic dermatitis and their characteristics in the real world
Experimental Dermatology · 2024
DOI: 10.1111/exd.15175 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Dermatology, 2024. Verfasst von Ayu Watanabe und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
Psossibility and appropriate timing of discontinuation of dupilumab for atopic dermatitis (AD) remain unclear. We explored the possibility of patients, who could maintain remission with topical therapy alone after withdrawing dupilumab in the real world. Furthermore, we identified their characteristics. All adult AD patients who initiated dupilumab from June 2018 to July 2022 and were treated with dupilumab for more than 3 months at our hospital were included in this study. The observation period was from June 2018 to July 2023. In 138 patients, 58 (42.0%) discontinued dupilumab at least once. Among them, 18 (13.0%) discontinued dupilumab but reinitiated dupilumab later due to exacerbation. Only seven patients (5.1%) could maintain remission with topical therapy alone after discontinuation of dupilumab, with characteristics of lower POEM, VAS of pruritus, serum levels of TARC and LDH, and neutrophil counts at baseline, and those of longer duration of dupilumab until its discontinuation (24.0 ± 13.3 vs. 12.8 ± 7.3 months) and lower EASI and affected BSA at the discontinuation of dupilumab. In 118 patients treated with dupilumab for at least 1 year, 38 patients (32.2%) discontinued at least once. Only four patients (3.4%) could maintain remission with topical therapy alone after discontinuation of dupilumab, with characteristics of lower POEM at baseline and lower EASI at the discontinuation of dupilumab. In conclusion, maintaining remission after withdrawing dupilumab is challenging. Discontinuation of dupilumab may be considered in patients with low baseline POEM, after more than 2 years of dupilumab treatment, with a substantial decrease in EASI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
ORCID-Profile: Masahiro Kamata
Zitieren
APA
Watanabe, A., Kamata, M., Okada, Y., Suzuki, S., Ito, M., Uchida, H., Chijiwa, C., Egawa, S., Hiura, A., Fukaya, S., Hayashi, K., Fukuyasu, A., Tanaka, T., Ishikawa, T., & Tada, Y. (2024). Possibility of maintaining remission with topical therapy alone after withdrawal of dupilumab in Japanese patients with atopic dermatitis and their characteristics in the real world. Experimental Dermatology. https://doi.org/10.1111/exd.15175
Vancouver
Watanabe A, Kamata M, Okada Y, Suzuki S, Ito M, Uchida H, et al. Possibility of maintaining remission with topical therapy alone after withdrawal of dupilumab in Japanese patients with atopic dermatitis and their characteristics in the real world. Experimental Dermatology. 2024. doi:10.1111/exd.15175
BibTeX
@article{Watanabe2024,
author = {Watanabe, Ayu and Kamata, Masahiro and Okada, Yoshiki and Suzuki, Shoya and Ito, Makoto and Uchida, Hideaki and Chijiwa, Chika and Egawa, Shota and Hiura, Azusa and Fukaya, Saki and Hayashi, Kotaro and Fukuyasu, Atsuko and Tanaka, Takamitsu and Ishikawa, Takeko and Tada, Yayoi},
title = {Possibility of maintaining remission with topical therapy alone after withdrawal of dupilumab in Japanese patients with atopic dermatitis and their characteristics in the real world},
journal = {Experimental Dermatology},
year = {2024},
doi = {10.1111/exd.15175}
}
EUVIMED